Pfizer And GSK Use Novel Funding Mechanism To Send Blockbuster Vaccines To World's Poorest Countries
This article was originally published in PharmAsia News
Pfizer and GlaxoSmithKline have agreed, after four years of negotiations, to supply their leading pneumococcal vaccines at significantly reduced prices to the world's poorest countries, signaling the first use of a novel funding mechanism that could create similar deals to bring new drugs to developing countries
You may also be interested in...
Serum Institute Of India Chairman Cyrus Poonawalla On How To Succeed In The Vaccines Business: An Interview With PharmAsia News
In a rare interview, Serum Institute of India Chairman Cyrus Poonawalla discusses his determination to keep vaccine prices low for India’s masses and his ongoing battles with multinational pharma companies.
GAVI Alliance Builds On Matching Fund On Heels Of Pfizer And GSK Vaccine Deal For Developing Countries
GAVI brings on new funding partners for immunization, supplementing expanded pneumococcal vaccine supply agreements with Pfizer and GSK.
Bharat Biotech's rotavirus development is a public-private initiative with partners including the Indian government, CDC and NIH.